The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin

Norberto Perico, Andrea Remuzzi, Fabio Sangalli, Nadia Azzollini, Marilena Mister, Piero Ruggenenti, Giuseppe Remuzzi

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Evidence is available from animal and human studies that protein traffic through the glomerular capillary has a pathogenetic role in subsequent renal damage and that angiotensin-converting enzyme (ACE) inhibitors appear superior to other drugs in lowering proteinuria and the rate of renal function decline. This study compares the effect of ACE inhibition or angiotensin II (AnglI) receptor blockade on urinary protein excretion and renal hemodynamics in 20 patients with IgA glomerulonephritis randomized to receive enalapril (20 mg/d) or irbesartan (100 mg/d) for 28 d in a double- blind study with two parallel groups. This study also evaluated whether addition of indomethacin (75 mg twice a day) to each of the two treatments resulted in a more potent antiproteinuric effect. Enalapril alone reduced total protein excretion (61% change from baseline) and fractional clearance of albumin without changes in GFR and minor elevation in renal plasma flow. Also, patients randomized to receive the AngII receptor antagonist irbesartan for 28 d had lower proteinuria (55% change from baseline) and fractional clearance of albumin at the end of the treatment period with similar renal hemodynamic changes. When indomethacin was added to enalapril treatment, a further significant reduction in urinary proteins and fractional albumin clearance was observed. In patients given irbesartan, the addition of indomethacin further reduced proteinuria and fractional clearance of albumin. The combined therapy with enalapril or irbesartan and indomethacin did not significantly affect GFR and renal plasma flow compared with baseline. These findings indicate that in patients with IgA glomerulonephritis the antiproteinuric effect of blocking AngII activity by either ACE inhibitors or AngII receptor antagonists is potentiated by indomethacin, an effect that occurred without impairment of renal function.

Original languageEnglish
Pages (from-to)2308-2317
Number of pages10
JournalJournal of the American Society of Nephrology
Volume9
Issue number12
Publication statusPublished - Dec 1998

Fingerprint

irbesartan
Angiotensins
Enalapril
Indomethacin
Immunoglobulin A
Albumins
Proteinuria
Renal Plasma Flow
Kidney
Glomerulonephritis
Angiotensin-Converting Enzyme Inhibitors
Proteins
Hemodynamics
Angiotensin Receptors
Peptidyl-Dipeptidase A
Therapeutics
Double-Blind Method
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Nephrology

Cite this

The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. / Perico, Norberto; Remuzzi, Andrea; Sangalli, Fabio; Azzollini, Nadia; Mister, Marilena; Ruggenenti, Piero; Remuzzi, Giuseppe.

In: Journal of the American Society of Nephrology, Vol. 9, No. 12, 12.1998, p. 2308-2317.

Research output: Contribution to journalArticle

Perico, Norberto ; Remuzzi, Andrea ; Sangalli, Fabio ; Azzollini, Nadia ; Mister, Marilena ; Ruggenenti, Piero ; Remuzzi, Giuseppe. / The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. In: Journal of the American Society of Nephrology. 1998 ; Vol. 9, No. 12. pp. 2308-2317.
@article{6736f99c438945399dbaf2f6f1e0878c,
title = "The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin",
abstract = "Evidence is available from animal and human studies that protein traffic through the glomerular capillary has a pathogenetic role in subsequent renal damage and that angiotensin-converting enzyme (ACE) inhibitors appear superior to other drugs in lowering proteinuria and the rate of renal function decline. This study compares the effect of ACE inhibition or angiotensin II (AnglI) receptor blockade on urinary protein excretion and renal hemodynamics in 20 patients with IgA glomerulonephritis randomized to receive enalapril (20 mg/d) or irbesartan (100 mg/d) for 28 d in a double- blind study with two parallel groups. This study also evaluated whether addition of indomethacin (75 mg twice a day) to each of the two treatments resulted in a more potent antiproteinuric effect. Enalapril alone reduced total protein excretion (61{\%} change from baseline) and fractional clearance of albumin without changes in GFR and minor elevation in renal plasma flow. Also, patients randomized to receive the AngII receptor antagonist irbesartan for 28 d had lower proteinuria (55{\%} change from baseline) and fractional clearance of albumin at the end of the treatment period with similar renal hemodynamic changes. When indomethacin was added to enalapril treatment, a further significant reduction in urinary proteins and fractional albumin clearance was observed. In patients given irbesartan, the addition of indomethacin further reduced proteinuria and fractional clearance of albumin. The combined therapy with enalapril or irbesartan and indomethacin did not significantly affect GFR and renal plasma flow compared with baseline. These findings indicate that in patients with IgA glomerulonephritis the antiproteinuric effect of blocking AngII activity by either ACE inhibitors or AngII receptor antagonists is potentiated by indomethacin, an effect that occurred without impairment of renal function.",
author = "Norberto Perico and Andrea Remuzzi and Fabio Sangalli and Nadia Azzollini and Marilena Mister and Piero Ruggenenti and Giuseppe Remuzzi",
year = "1998",
month = "12",
language = "English",
volume = "9",
pages = "2308--2317",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "12",

}

TY - JOUR

T1 - The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin

AU - Perico, Norberto

AU - Remuzzi, Andrea

AU - Sangalli, Fabio

AU - Azzollini, Nadia

AU - Mister, Marilena

AU - Ruggenenti, Piero

AU - Remuzzi, Giuseppe

PY - 1998/12

Y1 - 1998/12

N2 - Evidence is available from animal and human studies that protein traffic through the glomerular capillary has a pathogenetic role in subsequent renal damage and that angiotensin-converting enzyme (ACE) inhibitors appear superior to other drugs in lowering proteinuria and the rate of renal function decline. This study compares the effect of ACE inhibition or angiotensin II (AnglI) receptor blockade on urinary protein excretion and renal hemodynamics in 20 patients with IgA glomerulonephritis randomized to receive enalapril (20 mg/d) or irbesartan (100 mg/d) for 28 d in a double- blind study with two parallel groups. This study also evaluated whether addition of indomethacin (75 mg twice a day) to each of the two treatments resulted in a more potent antiproteinuric effect. Enalapril alone reduced total protein excretion (61% change from baseline) and fractional clearance of albumin without changes in GFR and minor elevation in renal plasma flow. Also, patients randomized to receive the AngII receptor antagonist irbesartan for 28 d had lower proteinuria (55% change from baseline) and fractional clearance of albumin at the end of the treatment period with similar renal hemodynamic changes. When indomethacin was added to enalapril treatment, a further significant reduction in urinary proteins and fractional albumin clearance was observed. In patients given irbesartan, the addition of indomethacin further reduced proteinuria and fractional clearance of albumin. The combined therapy with enalapril or irbesartan and indomethacin did not significantly affect GFR and renal plasma flow compared with baseline. These findings indicate that in patients with IgA glomerulonephritis the antiproteinuric effect of blocking AngII activity by either ACE inhibitors or AngII receptor antagonists is potentiated by indomethacin, an effect that occurred without impairment of renal function.

AB - Evidence is available from animal and human studies that protein traffic through the glomerular capillary has a pathogenetic role in subsequent renal damage and that angiotensin-converting enzyme (ACE) inhibitors appear superior to other drugs in lowering proteinuria and the rate of renal function decline. This study compares the effect of ACE inhibition or angiotensin II (AnglI) receptor blockade on urinary protein excretion and renal hemodynamics in 20 patients with IgA glomerulonephritis randomized to receive enalapril (20 mg/d) or irbesartan (100 mg/d) for 28 d in a double- blind study with two parallel groups. This study also evaluated whether addition of indomethacin (75 mg twice a day) to each of the two treatments resulted in a more potent antiproteinuric effect. Enalapril alone reduced total protein excretion (61% change from baseline) and fractional clearance of albumin without changes in GFR and minor elevation in renal plasma flow. Also, patients randomized to receive the AngII receptor antagonist irbesartan for 28 d had lower proteinuria (55% change from baseline) and fractional clearance of albumin at the end of the treatment period with similar renal hemodynamic changes. When indomethacin was added to enalapril treatment, a further significant reduction in urinary proteins and fractional albumin clearance was observed. In patients given irbesartan, the addition of indomethacin further reduced proteinuria and fractional clearance of albumin. The combined therapy with enalapril or irbesartan and indomethacin did not significantly affect GFR and renal plasma flow compared with baseline. These findings indicate that in patients with IgA glomerulonephritis the antiproteinuric effect of blocking AngII activity by either ACE inhibitors or AngII receptor antagonists is potentiated by indomethacin, an effect that occurred without impairment of renal function.

UR - http://www.scopus.com/inward/record.url?scp=0031724898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031724898&partnerID=8YFLogxK

M3 - Article

C2 - 9848785

AN - SCOPUS:0031724898

VL - 9

SP - 2308

EP - 2317

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 12

ER -